Compounds > bosentan anhydrous
Page last updated: 2024-08-26

bosentan anhydrous and Adverse Drug Event

bosentan anhydrous has been researched along with Adverse Drug Event in 11 studies

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (36.36)29.6817
2010's7 (63.64)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S1
Ding, D; Fang, H; Kelly, R; Liu, Z; Shi, Q; Tong, W1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Feinstein, JA; Ivy, DD; Maxey, DM; Ogawa, MT1
Hauben, M; Maignen, F; Tsintis, P1
Du, J; He, B; Jin, H; Li, X; Lin, G; Tang, C; Zhang, F1
Hussar, DA1
Fujimoto, K; Ikenoya, S1
Riemekasten, G1
Austin, MJ; Callender, ME; Heneghan, MA; Knisely, AS; McDougall, NI; O'Grady, JG; Rela, M; Sizer, E; Wendon, JA; Wilson, C1

Reviews

2 review(s) available for bosentan anhydrous and Adverse Drug Event

ArticleYear
Meta-analysis of randomized controlled trials on treatment of pulmonary arterial hypertension.
    Circulation journal : official journal of the Japanese Circulation Society, 2010, Volume: 74, Issue:7

    Topics: Antihypertensive Agents; Bosentan; Drug-Related Side Effects and Adverse Reactions; Humans; Hypertension, Pulmonary; Iloprost; Piperazines; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents

2010
[Pharmacological characteristics and clinical efficacy of bosentan].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2005, Volume: 126, Issue:6

    Topics: Animals; Antihypertensive Agents; Bosentan; Disease Models, Animal; Drug-Related Side Effects and Adverse Reactions; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Humans; Hypertension, Pulmonary; In Vitro Techniques; Nitric Oxide Synthase; Randomized Controlled Trials as Topic; Sulfonamides; Vasoconstriction

2005

Other Studies

9 other study(ies) available for bosentan anhydrous and Adverse Drug Event

ArticleYear
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors

2012
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
    PLoS computational biology, 2011, Volume: 7, Issue:12

    Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Models, Biological; Predictive Value of Tests

2011
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Food and Drug Administration (FDA) postmarket reported side effects and adverse events associated with pulmonary hypertension therapy in pediatric patients.
    Pediatric cardiology, 2013, Volume: 34, Issue:7

    Topics: Adolescent; Antihypertensive Agents; Bosentan; Child; Child, Preschool; Drug-Related Side Effects and Adverse Reactions; Epoprostenol; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Incidence; Infant; Infant, Newborn; Male; Piperazines; Product Surveillance, Postmarketing; Purines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Sulfones; United States; United States Food and Drug Administration; Vasodilator Agents

2013
Modelling the time to onset of adverse reactions with parametric survival distributions: a potential approach to signal detection and evaluation.
    Drug safety, 2010, May-01, Volume: 33, Issue:5

    Topics: Adverse Drug Reaction Reporting Systems; Antihypertensive Agents; Bacterial Infections; Bosentan; Drug-Related Side Effects and Adverse Reactions; Humans; Kaplan-Meier Estimate; Liver; Models, Statistical; Models, Theoretical; Pharmacology; Sulfonamides; Time Factors; Tuberculosis, Pulmonary; Tumor Necrosis Factor-alpha

2010
New drugs 2002, part III.
    Nursing, 2002, Volume: 32, Issue:7

    Topics: Adenine; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Antihypertensive Agents; Antirheumatic Agents; Bone Resorption; Bosentan; Cephalosporins; Darbepoetin alfa; Diphosphonates; Drug Approval; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Erythropoietin; Heart Failure; Humans; Hypoglycemic Agents; Imidazoles; Indoles; Insulin; Insulin Aspart; Interleukin 1 Receptor Antagonist Protein; Natriuretic Agents; Natriuretic Peptide, Brain; Organophosphonates; Organophosphorus Compounds; Protein C; Recombinant Proteins; Serotonin Receptor Agonists; Sialoglycoproteins; Sulfonamides; Tenofovir; Tryptamines; Zoledronic Acid

2002
[Endothelin receptor antagonism in routine clinical care].
    Krankenpflege Journal, 2005, Volume: 43, Issue:7-10

    Topics: Bosentan; Controlled Clinical Trials as Topic; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Prognosis; Scleroderma, Systemic; Sulfonamides; Survival Analysis

2005
Safety and efficacy of combined use of sildenafil, bosentan, and iloprost before and after liver transplantation in severe portopulmonary hypertension.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2008, Volume: 14, Issue:3

    Topics: Adult; Blood Pressure; Bosentan; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Humans; Hypertension, Portal; Hypertension, Pulmonary; Iloprost; Liver Diseases; Liver Transplantation; Male; Piperazines; Pulmonary Artery; Purines; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents

2008